Blue Jay Capital Management LLC Sells 33,445 Shares of PRA Health Sciences, Inc. (PRAH)

Blue Jay Capital Management LLC trimmed its holdings in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 23.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,555 shares of the medical research company’s stock after selling 33,445 shares during the quarter. PRA Health Sciences comprises about 5.4% of Blue Jay Capital Management LLC’s holdings, making the stock its 7th largest position. Blue Jay Capital Management LLC owned 0.17% of PRA Health Sciences worth $7,993,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the stock. First Bank & Trust grew its position in PRA Health Sciences by 1.6% during the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares in the last quarter. Renaissance Group LLC grew its position in PRA Health Sciences by 2.5% during the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after buying an additional 126 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in PRA Health Sciences by 0.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock worth $1,428,000 after buying an additional 140 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in PRA Health Sciences by 1.9% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after buying an additional 160 shares in the last quarter. Institutional investors and hedge funds own 98.37% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Blue Jay Capital Management LLC Sells 33,445 Shares of PRA Health Sciences, Inc. (PRAH)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://ledgergazette.com/2017/09/24/blue-jay-capital-management-llc-sells-33445-shares-of-pra-health-sciences-inc-prah.html.

In other news, VP Linda Baddour sold 100,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $7,485,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $711,075,000.00. The disclosure for this sale can be found here. Insiders have sold 10,000,000 shares of company stock worth $748,500,000 over the last three months. Corporate insiders own 2.10% of the company’s stock.

PRAH has been the subject of several recent analyst reports. Jefferies Group LLC set a $73.00 target price on PRA Health Sciences and gave the stock a “buy” rating in a research report on Thursday, June 1st. Credit Suisse Group restated an “outperform” rating and set a $76.00 target price (up from $69.00) on shares of PRA Health Sciences in a research report on Tuesday, June 6th. Bank of America Corporation initiated coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 target price for the company. Citigroup Inc. restated a “buy” rating and set a $90.00 target price (up from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Finally, BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $84.22.

Shares of PRA Health Sciences, Inc. (PRAH) traded down 0.78% during midday trading on Friday, reaching $75.09. The company’s stock had a trading volume of 360,645 shares. The company’s 50-day moving average price is $75.71 and its 200-day moving average price is $70.59. PRA Health Sciences, Inc. has a 12 month low of $50.87 and a 12 month high of $80.99. The company has a market cap of $4.70 billion, a PE ratio of 48.48 and a beta of 0.45.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.10). The company had revenue of $457.90 million for the quarter, compared to analysts’ expectations of $447.79 million. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. PRA Health Sciences’s quarterly revenue was up .5% compared to the same quarter last year. During the same period last year, the firm earned $0.63 earnings per share. On average, equities analysts anticipate that PRA Health Sciences, Inc. will post $3.19 EPS for the current fiscal year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply